Drug research

Relacorilant

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as CORT125134

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing SyndromeNCT03697109	Corcept Therapeutics	Phase 3	Completed	2024-04-08Actual
Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic AdenocarcinomaNCT07259317	Corcept Therapeutics	Phase 2	Recruiting	2027-09Estimated
Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal CancerNCT03776812	Corcept Therapeutics	Phase 2	Completed	2021-03-16Actual
A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal AdenomasNCT04308590	Corcept Therapeutics	Phase 3	Completed	2024-09-19Actual

Corcept TherapeuticsCompletedPrimary completion: 2024-04-08 · Actual

Trial details

Corcept TherapeuticsRecruitingPrimary completion: 2027-09 · Estimated

Trial details

Corcept TherapeuticsCompletedPrimary completion: 2021-03-16 · Actual

Trial details

Corcept TherapeuticsCompletedPrimary completion: 2024-09-19 · Actual

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.